期刊文献+

他汀类药物安全性再认识 被引量:5

原文传递
导出
摘要 大量研究奠定了他汀类药物在心血管疾病一级和二级预防中不可动摇的地位.强化调脂的理念已经深入临床。大剂量他汀类药物治疗对肝脏和肌肉潜在的不良反应已得到医患的重视,而近年来对他汀类药物肾脏损害、神经系统不良反应、新发肿瘤和糖尿病等的担忧和争论始终没有停止。因此,
作者 边素艳 叶平
出处 《内科理论与实践》 2011年第6期416-420,共5页 Journal of Internal Medicine Concepts & Practice
  • 相关文献

参考文献10

  • 1The Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian simvastatin survival study(4S)[J].Lancet,1994,344(8934):1383-1389.
  • 2Bonovas S,Sitaras NM.Does pravastatin promote cancer in elderly patients? A meta-analysis[J].CMAJ,2007,176(5):649.
  • 3McMurray JJ,Kjekshus J,Gullestad L,et al.Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure(CORONA)[J].Circulation,2009,120(22):2188-2196.
  • 4Hsia J,MacFadyen JG,Monyak J,et al.Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin.The JUPITER trial(justification for the use of statins in prevention:an intervention trial evaluating rosuvastatin)[J].J Am Coll Cardiol,2011,57(16):1666-1675.
  • 5Sharp Collaborative Group.Study of heart and renal protection(SHARP):randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438patients with chronic kidney disease[J].Am Heart J,2010,160(5):785-794,e10.
  • 6The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID)Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med,1998,339(19):1349-1357.
  • 7Streja L,Packard CJ,Shepherd J,et al.Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the west of scotland coronary prevention study(WOSCOPS)[J].Am J Cardiol,2002,90(7):731-736.
  • 8Deedwania P,Stone PH,Bairey Merz CN,et al.Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease:results of the study assessing goals in the elderly (SAGE)[J].Circulation,2007,115(6):700-707.
  • 9McKenney JM,Davidson MH,Jacobson TA,et al.Final conclusions and recommendations of the national lipid association statin safety assessment task force[J].Am J Cardiol,2006,97(8A):89C-94C.
  • 10Heart Protection Study Collaborative Group.MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial[J].Lancet,2002,360(9326):7-22.

同被引文献89

  • 1杜瑞雪,叶平.2011年欧洲血脂异常管理指南解读[J].中国医学前沿杂志(电子版),2011,3(4):87-90. 被引量:9
  • 2杨士杰,李栋,姜达.辛伐他汀对荷瘤小鼠抑瘤作用的实验研究[J].河北医药,2006,28(7):573-574. 被引量:3
  • 3郭丽萍,罗建民.P21蛋白和生存素在美伐他汀诱导人非小细胞肺癌凋亡中的作用[J].解放军医学杂志,2006,31(9):873-875. 被引量:1
  • 4中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5224
  • 5Brass LM,Alberts M J, Sparks L. An assessment of statin safety by neurologists[ J ]. Am J Cardiol,2006,97 (8A) :86C - 88C.
  • 6Sassano A, Platanias LC. Statins in tumor suppression[J]. Cancer Lett,2008,260(1 2) : 11-19.
  • 7Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family ofdrugs as triggers of tumor-specific apoptosis[J]. Leukemia. 2002,16(4) : 508-519.
  • 8Denoyelle C, Vasse M, K rner M, et al. Cerivastatin, an in- hibitor of HMCrCoA reductase, inhibits the signaling path- ways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study[J]. Carcinogenesis, 2001 ,22(8) : 1139-1148.
  • 9HIGGINS JP, GREEN S. Cochrane Handbook for Systematic Reviews of Interventions VersionS. 0. 0 [updated February 2008][CP]. The Cochrane Collaboration,2008.
  • 10Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis[J]. JAMA,2006,295(1):74-80.

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部